Gary Weiss, MD
Hematology & Oncology · Webster, TXNPI 1215973961
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,300 of the $5,338 with a category attached, or 61.8%. Genentech USA, Inc. accounts for 88.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $4,740 and has fallen 96.7% since, to $156 in 2023.
Across 21 payments — averaging $254.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- E.r. Squibb & Sons, L.L.C.$153
- Sandoz$125
- Pharmaessentia USA Corporation$124
- Scilex Pharmaceuticals Inc.$42
- Pharmacosmos Therapeutics Inc.$32
- plus $123 from 8 others
What the payments were for
- Consulting fees$3,30062%
- Grants$1252%
- Travel & lodging$1,33025%
- Food & beverage$54910%
- Education$341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 6 | $4,740 |
| E.r. Squibb & Sons, L.L.C. | 3 | $153 |
| Sandoz | 1 | $125 |
| Pharmaessentia USA Corporation | 1 | $124 |
| Scilex Pharmaceuticals Inc. | 1 | $42 |
| Pharmacosmos Therapeutics Inc. | 1 | $32 |
| Merck | 1 | $25 |
| Sanofi | 1 | $22 |
| Eisai Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Emergent Biosolutions Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,338 in reported general payments places this provider in the 60th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Webster
- Alan RodneyWebster$445K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.